Last reviewed · How we verify
NCT05281744: Co-CARE-AD
Collaborative Care Coordination Program for Alzheimer's Disease and Related Dementias
NA trial testing Dementia Care Consultation program in Alzheimer's Disease and Related Dementias (ADRD) in 2,160 participants. Completed in 15 January 2026.
15 January 2026
Quick facts
| Lead sponsor | Harvard Pilgrim Health Care |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 2,160 |
| Start date | 27 May 2022 |
| Primary completion | 15 January 2026 |
| Estimated completion | 15 January 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dementia Care Consultation program
Conditions studied
- Alzheimer's Disease and Related Dementias (ADRD) — all drugs for Alzheimer's Disease and Related Dementias (ADRD) →
Sponsor
Harvard Pilgrim Health Care — full company profile →
Who can join
18 and older, any sex, with Alzheimer's Disease and Related Dementias (ADRD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, pragmatic clinical trial to evaluate the effectiveness of a collaborative care-coordination program embedded in a health plan for people living with Alzheimer's disease and related dementias (ADRD) and their care partners versus usual care. The study population will include community-dwelling Medicare Advantage members living with ADRD and their care partners. Outcomes will be healthcare utilization outcomes of individuals with ADRD and include emergency department visits, outpatient visits, avoidable emergency department visits, and admission to long-term care facilities.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pragmatic guidance for embedding pragmatic clinical trials in health plans: Large simple trials aren't so simple.
Cocoros NM, Gurwitz JH, Cziraky MJ, Granger CB, et al · · 2023 · cited 6× · PMID 37322894 · DOI 10.1177/17407745231160459
Verify or expand the search:
- PubMed search for NCT05281744
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Harvard Pilgrim Health Care trials
Trials by the same sponsor.
- NCT06516627 — Front-of-Package Nutrition Labels · NA · completed
- NCT06584539 — Eco-labels on Restaurant Menus · NA · completed
- NCT06384911 — InvesT1D: Promoting Adolescent Investment in Diabetes Care · NA · recruiting
- NCT05423743 — INSPIRE Trial for Abdominal Infections · NA · completed
- NCT05423756 — INSPIRE Trial for Skin and Soft Tissue Infections · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05281744 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Harvard Pilgrim Health Care
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05281744.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing